| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000045040 |
| Receipt No. | R000051446 |
| Scientific Title | A confirmation study for improving cognitive function with consumption of the test food: A randomized double-blind placebo-controlled trial |
| Date of disclosure of the study information | 2021/08/02 |
| Last modified on | 2022/06/28 (Ver. 5) |
| Basic information | ||
| Public title | A confirmation study for improving cognitive function with consumption of the test food | |
| Acronym | A confirmation study for improving cognitive function with consumption of the test food | |
| Scientific Title | A confirmation study for improving cognitive function with consumption of the test food: A randomized double-blind placebo-controlled trial | |
| Scientific Title:Acronym | A confirmation study for improving cognitive function with consumption of the test food | |
| Region |
|
|
| Condition | |||
| Condition | Healthy Japanese subjects | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To verify the effects of consumption of the test food on cognitive function in healthy Japanese men and women aged 40 or more |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | The measured value of the standardized score of composite memory at 12 weeks after consumption (12w) |
| Key secondary outcomes | 1. The amount of change of the standardized score of composite memory between screening (before consumption; Scr) and 12w
2. The measured values of the standardized scores of Neurocognition Index (NCI), verbal memory, visual memory, psychomotor speed, reaction time, complex attention, cognitive flexibility, processing speed, executive function, social acuity, reasoning, working memory, sustained attention, simple attention and motor speed at 12w 3. The amounts of changes of the standardized scores of NCI, verbal memory, visual memory, psychomotor speed, reaction time, complex attention, cognitive flexibility, processing speed, executive function, social acuity, reasoning, working memory, sustained attention, simple attention and motor speed between Scr and 12w |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | YES |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Duration: 12 weeks
Test food: Food containing Citrus depressa extract powder Administration: Take one capsule with water after breakfast * Daily dose should be taken within the day. If you forget to take the test food, take it as soon as you remember within the day. |
|
| Interventions/Control_2 | Duration: 12 weeks
Test food: Food not containing Citrus depressa extract powder Administration: Take one capsule with water after breakfast * Daily dose should be taken within the day. If you forget to take the test food, take it as soon as you remember within the day. |
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Japanese
2. Men or women 3. Subjects aged 40 or more 4. Healthy subjects 5. Subjects who are aware of the decline in their memory function 6. Subjects who are judged as eligible to participate in the study by the physician 7. Subjects whose scoring of Mini Mental State Examinination (MMSE)-J is 24 or more 8. Subjects who have a "yes" in the validity indicator of Cognitrax on both verbal memory and visual memory 9. Subjects who have a relatively low standardized score of composite memory by Cognitrax |
|||
| Key exclusion criteria | Subjects who
1. are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction 2. have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disease, kidney disease, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. have dementia 5. have mental health issues such as depression disorder, attention deficit/hyperactivity disorder (ADHD), or other issues 6. are smoker at the time of the agreement to participate in this trial or plan to smoke during this trial 7. plan to have surgery from first consumption to two weeks after last consumption 8. take "Foods for Specified Health Uses", "Foods with Functional Claims", or other functional food/beverage at least four times a week 9. take supplements related to improving cognitive functions, such as docosahexaenoic acid, eicosapentaenoic acid, ginkgo leaf extract, tocotrienol, astaxanthin, gamma-aminobutyric acid, phosphatidylserine, and plasmalogen at least four times a week 10. take blue-backed fish such as sardines, mackerel, and saury at least four times a week 11. use devices, equipment, and applications that may affect cognitive functions (e.g., brain training puzzles, brain training games) in daily 12. are currently taking medications (including herbal medicines) and supplements 13. are allergic to medications and/or the test-food-related products (particularly citrus fruit) 14. are pregnant, lactation, or planning to become pregnant 15. have been enrolled in other clinical trials within the last 28 days before the agreement to participate in this trial or plan to participate another trial during this trial 16. are judged as ineligible to participate in the study by the physician |
|||
| Target sample size | 36 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Medical Corporation Seishinkai, Takara Clinic
|
||||||
| Division name | Director | ||||||
| Zip code | 141-0022 | ||||||
| Address | 9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan | ||||||
| TEL | 03-5793-3623 | ||||||
| t-takara@takara-clinic.com | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | ORTHOMEDICO Inc. | ||||||
| Division name | R&D Department | ||||||
| Zip code | 112-0002 | ||||||
| Address | 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan. | ||||||
| TEL | 03-3818-0610 | ||||||
| Homepage URL | |||||||
| nao@orthomedico.jp | |||||||
| Sponsor | |
| Institute | ORTHOMEDICO Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Okinawa TLO Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Medical Corporation Seishinkai, Takara Clinic
Nerima Medical Association, Minami-machi Clinic |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | the ethical committee of the Takara Clinic, Medical Corporation Seishinkai |
| Address | 9F Taisei Building, 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan. |
| Tel | 03-5793-3623 |
| IRB@takara-clinic.com | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan) 南町医院 (東京都) Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 40 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051446 |